A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
Status:
Completed
Trial end date:
2018-06-12
Target enrollment:
Participant gender:
Summary
This two-part, Phase 1 protocol will be the first clinical study of ABI-H0731. Part I will be
a Phase 1a dose-ranging assessment of ABI-H0731 in healthy adult volunteers. If the
dose-related safety, tolerability and pharmacokinetics (PK) of ABI-H0731 in human volunteers
are deemed satisfactory, then the study will advance to Part II, a Phase 1b dose-ranging
assessment of ABI-H0731 in non-cirrhotic, CHB patients.